Accelerate Diagnostics Stock Performance
| AXDX Stock | USD 0.93 0.02 2.00% |
The firm shows a Beta (market volatility) of 0.35, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Accelerate Diagnostics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Accelerate Diagnostics is expected to be smaller as well. Accelerate Diagnostics has an expected return of -0.35%. Please make sure to confirm Accelerate Diagnostics total risk alpha, as well as the relationship between the kurtosis and price action indicator , to decide if Accelerate Diagnostics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Accelerate Diagnostics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's fundamental indicators remain fairly strong which may send shares a bit higher in May 2024. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Last Split Factor 1:10 | Last Split Date 2023-07-12 |
1 | Disposition of 1000 shares by David Patience of Accelerate Diagnostics subject to Rule 16b-3 | 02/26/2024 |
2 | Accelerate Diagnostics Scheduled Call to Review 2023 Fourth Quarter and Full Year Results. | 03/07/2024 |
3 | Accelerate Diagnostics Scheduled to Post Quarterly Earnings on Thursday - Defense World | 03/20/2024 |
4 | Accelerate Diagnostics Reports Q4 Loss, Misses Revenue Estimates | 03/28/2024 |
5 | Earnings call Accelerate Diagnostics reports mixed results amid progress | 04/01/2024 |
6 | Accelerate Diagnostics Receives New Coverage from Analysts at StockNews.com - Defense World | 04/03/2024 |
7 | Disposition of 35523 shares by Jack Phillips of Accelerate Diagnostics subject to Rule 16b-3 | 04/04/2024 |
8 | Disposition of 40633 shares by Mertz Larry Michael of Accelerate Diagnostics subject to Rule 16b-3 | 04/09/2024 |
9 | Accelerate Diagnostics Coverage Initiated at StockNews.com - Defense World | 04/11/2024 |
10 | Disposition of 1000 shares by Jack Phillips of Accelerate Diagnostics subject to Rule 16b-3 | 04/12/2024 |
11 | Disposition of 59928 shares by Jack Phillips of Accelerate Diagnostics subject to Rule 16b-3 | 04/16/2024 |
12 | Disposition of 350 shares by David Patience of Accelerate Diagnostics at 0.96 subject to Rule 16b-3 | 04/19/2024 |
| Begin Period Cash Flow | 34.9 M |
Accelerate |
Accelerate Diagnostics Relative Risk vs. Return Landscape
If you would invest 128.00 in Accelerate Diagnostics on January 26, 2024 and sell it today you would lose (34.90) from holding Accelerate Diagnostics or give up 27.27% of portfolio value over 90 days. Accelerate Diagnostics is currently does not generate positive expected returns and assumes 5.7105% risk (volatility on return distribution) over the 90 days horizon. In different words, 50% of stocks are less volatile than Accelerate, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Accelerate Diagnostics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Accelerate Diagnostics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Accelerate Diagnostics, and traders can use it to determine the average amount a Accelerate Diagnostics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0611
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | AXDX |
Estimated Market Risk
| 5.71 actual daily | 50 50% of assets are less volatile |
Expected Return
| -0.35 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.06 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Accelerate Diagnostics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Accelerate Diagnostics by adding Accelerate Diagnostics to a well-diversified portfolio.
Accelerate Diagnostics Fundamentals Growth
Accelerate Stock prices reflect investors' perceptions of the future prospects and financial health of Accelerate Diagnostics, and Accelerate Diagnostics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Accelerate Stock performance.
| Return On Asset | -0.7 | ||||
| Operating Margin | (3.54) % | ||||
| Current Valuation | 45.23 M | ||||
| Shares Outstanding | 21.66 M | ||||
| Price To Earning | (15.18) X | ||||
| Price To Sales | 1.60 X | ||||
| Revenue | 12.06 M | ||||
| Gross Profit | 3.3 M | ||||
| EBITDA | (50.77 M) | ||||
| Net Income | (61.62 M) | ||||
| Cash And Equivalents | 36.77 M | ||||
| Cash Per Share | 0.45 X | ||||
| Total Debt | 39.22 M | ||||
| Debt To Equity | 2.76 % | ||||
| Current Ratio | 4.48 X | ||||
| Book Value Per Share | (1.36) X | ||||
| Cash Flow From Operations | (40.2 M) | ||||
| Earnings Per Share | (4.94) X | ||||
| Market Capitalization | 20.58 M | ||||
| Total Asset | 31.37 M | ||||
| Retained Earnings | (668.86 M) | ||||
| Working Capital | 12.43 M | ||||
| Current Asset | 91.68 M | ||||
| Current Liabilities | 4.45 M | ||||
About Accelerate Diagnostics Performance
To evaluate Accelerate Diagnostics Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Accelerate Diagnostics generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Accelerate Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Accelerate Diagnostics market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Accelerate's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 127.05 | 120.70 | |
| Return On Tangible Assets | (1.96) | (1.87) | |
| Return On Capital Employed | (2.79) | (2.66) | |
| Return On Assets | (1.96) | (1.87) | |
| Return On Equity | 3.10 | 3.25 |
Things to note about Accelerate Diagnostics performance evaluation
Checking the ongoing alerts about Accelerate Diagnostics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Accelerate Diagnostics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Accelerate Diagnostics generated a negative expected return over the last 90 days | |
| Accelerate Diagnostics has high historical volatility and very poor performance | |
| Accelerate Diagnostics has some characteristics of a very speculative penny stock | |
| Accelerate Diagnostics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 12.06 M. Net Loss for the year was (61.62 M) with profit before overhead, payroll, taxes, and interest of 3.3 M. | |
| Accelerate Diagnostics currently holds about 36.77 M in cash with (40.2 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.45. | |
| Accelerate Diagnostics has a frail financial position based on the latest SEC disclosures | |
| Roughly 37.0% of the company shares are held by company insiders | |
| Latest headline from MacroaxisInsider: Disposition of 350 shares by David Patience of Accelerate Diagnostics at 0.96 subject to Rule 16b-3 |
- Analyzing Accelerate Diagnostics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Accelerate Diagnostics' stock is overvalued or undervalued compared to its peers.
- Examining Accelerate Diagnostics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Accelerate Diagnostics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Accelerate Diagnostics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Accelerate Diagnostics' stock. These opinions can provide insight into Accelerate Diagnostics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Accelerate Diagnostics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. For more information on how to buy Accelerate Stock please use our How to Invest in Accelerate Diagnostics guide.Note that the Accelerate Diagnostics information on this page should be used as a complementary analysis to other Accelerate Diagnostics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Complementary Tools for Accelerate Stock analysis
When running Accelerate Diagnostics' price analysis, check to measure Accelerate Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Accelerate Diagnostics is operating at the current time. Most of Accelerate Diagnostics' value examination focuses on studying past and present price action to predict the probability of Accelerate Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Accelerate Diagnostics' price. Additionally, you may evaluate how the addition of Accelerate Diagnostics to your portfolios can decrease your overall portfolio volatility.
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories |
Is Accelerate Diagnostics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Accelerate Diagnostics. If investors know Accelerate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Accelerate Diagnostics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.94) | Revenue Per Share 0.966 | Quarterly Revenue Growth 0.019 | Return On Assets (0.70) |
The market value of Accelerate Diagnostics is measured differently than its book value, which is the value of Accelerate that is recorded on the company's balance sheet. Investors also form their own opinion of Accelerate Diagnostics' value that differs from its market value or its book value, called intrinsic value, which is Accelerate Diagnostics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Accelerate Diagnostics' market value can be influenced by many factors that don't directly affect Accelerate Diagnostics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Accelerate Diagnostics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Accelerate Diagnostics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Accelerate Diagnostics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.